Selective killing of malignant CD4+CD7− T-cells over normal bystander cells was observed in vitro, which suggests that Pc 4-PDT can potentially be utilized as a target-specific anticancer therapy for malignancies such as CTCL. This evidence concerns the gene CD7 and primary cutaneous T-cell non-Hodgkin lymphoma.